US › Healthcare

Inventiva Sa (IVA)

US · Healthcare · Biotechnology

$4.51+6.12%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$28,785
Revenue YoY
-98.9%
Net profit
$-176.9M
Profit YoY
-260.9%
EPS
$0.00
EPS estimate
$-0.34
Net margin
-614,683.2%

EPS came in at 0.00 against a street estimate of -0.34 — a beat of 100.0%.

Key statistics

Market cap
$1.06B
Forward P/E
0.0
P/B
2.10
Book value
$-0.17
EPS (TTM)
$-2.18
52-week high
$7.98
52-week low
$3.16
50-day MA
$4.25
200-day MA
$5.07
Beta
0.89

Analyst view

Analysts rate Inventiva Sa a strong buy (6 buy, 1 hold, 0 sell out of 7) with an average price target of $15.11.

Shareholding

Institutions
28.00%

Largest institutional holders

FundStake
Samsara BioCapital, LLC2.20%
Caligan Partners LP2.11%
Paradigm Biocapital Advisors LP1.69%
Andera Partners1.54%
Millennium Management LLC1.26%
Trails Edge Capital Partners, LP1.13%
Franklin Resources Inc1.04%
SymBiosis Capital Partners, LLC1.00%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Inventiva Sa — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.